# A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

> **NCT04009499** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **UCB Biopharma SRL** · enrollment: 1131 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Bimekizumab

## Key facts

- **NCT ID:** NCT04009499
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-13
- **Primary completion:** 2026-05-25
- **Final completion:** 2026-05-25
- **Target enrollment:** 1131 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04009499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04009499, "A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT04009499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*